Jun 6, 2014 by Eric Thomasson3 Pharma Giants Battling for Immuno-Oncology DominanceThe run to see who can get out in front in the promising immuno-oncology field is a high stakes battle.
Jun 6, 2014 by Eric Thomasson2 Small-Cap Biotechs for Your WatchlistOmeros and Dynavax each have drugs that could produce huge gains. Risk of investment is also mitigated by certain factors in each company.
Jun 4, 2014 by Eric ThomassonCan Anyone Dethrone Gilead?Gilead is the clear leader in hepatitis C treatment. But other treatments appear to be solid and will produce successful results for investors.
